| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | C->U-editing enzyme APOBEC-1, 354-, Apolipoprotein B mRNA-editing enzyme 1, HEPR, APOBEC1 |
| Entrez GeneID | 339 |
| WB Predicted band size | 28.2kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This Apobec1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 7-36 amino acids from the N-terminal region of human Apobec1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于Apobec1(N-term)抗体的参考文献，简要概括了其研究背景和抗体应用场景：
---
1. **文献名称**: *Molecular cloning of an apolipoprotein B messenger RNA editing protein*
**作者**: Teng B., Burant C.F., Davidson N.O.
**摘要**: 该研究首次克隆了Apobec1基因，并制备了针对其N端结构域的抗体，用于检测大鼠和小鼠肝脏中Apobec1蛋白的表达，证实其在ApoB mRNA编辑中的关键作用。
---
2. **文献名称**: *Complementation of apolipoprotein B mRNA editing by human liver accompanied by particle assembly*
**作者**: Hirano K., Young S.G., Farese R.V. et al.
**摘要**: 研究利用Apobec1(N-term)抗体进行免疫沉淀实验，揭示了人类肝脏中Apobec1与其他辅助蛋白(如ACF)形成复合物的机制，并验证了抗体在检测编辑酶复合物中的特异性。
---
3. **文献名称**: *Overexpression of APOBEC-1 results in mooring sequence-dependent promiscuous RNA editing*
**作者**: Sowden M.P., Ballatori N., Jensen H. et al.
**摘要**: 通过构建Apobec1过表达细胞模型，结合N端抗体的Western blot分析，证明Apobec1的异常表达会导致非靶向RNA编辑，强调了其N端结构域在底物识别中的重要性。
---
**注**：上述文献年份较早(1993-2002)，如需近年研究建议补充关键词(如“Apobec1 antibody validation”或“N-terminal epitope”)进一步检索。部分抗体应用细节可能需要结合供应商技术文档(如CST或Santa Cruz的抗体说明书)进行验证。
The Apobec1 (N-term) antibody is a targeted immunological tool designed to detect the N-terminal region of Apolipoprotein B mRNA-editing enzyme catalytic subunit 1 (Apobec1), a key enzyme in RNA editing. Apobec1 is best known for its role in post-transcriptional modification of apolipoprotein B (apoB) mRNA, where it catalyzes the deamination of cytidine to uridine at a specific site, converting apoB-100 to apoB-48 in the small intestine. This editing process is critical for lipid metabolism and lipoprotein assembly. Dysregulation of Apobec1 has been implicated in metabolic disorders, atherosclerosis, and certain cancers.
The Apobec1 (N-term) antibody is commonly used in research to study the expression, localization, and function of Apobec1 in tissues such as the liver, intestine, and adipose tissue. It is employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein levels in both physiological and pathological contexts. The antibody's specificity for the N-terminal domain ensures recognition of full-length Apobec1. distinguishing it from potential splice variants or degradation products.
Researchers utilize this antibody to explore Apobec1's involvement in RNA-editing-independent roles, including DNA repair and innate immune responses. Its validation often includes knockout controls or siRNA-based silencing to confirm target specificity. By enabling precise detection, the Apobec1 (N-term) antibody supports investigations into metabolic diseases, cancer biology, and therapeutic targeting of RNA-editing pathways.
×
